Lakewood-Amedex Biotherapeutics (NASDAQ:LABT) Raised to Sell at Wall Street Zen

Lakewood-Amedex Biotherapeutics (NASDAQ:LABT) was upgraded by analysts at Wall Street Zen from a “strong sell” rating to a “sell” rating in a note issued to investors on Sunday, Wall Street Zen reports.

Separately, Weiss Ratings started coverage on Lakewood-Amedex Biotherapeutics in a research note on Monday, July 20th. They issued a “sell (e-)” rating on the stock. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock presently has an average rating of “Sell”.

Lakewood-Amedex Biotherapeutics Price Performance

Shares of LABT opened at $1.88 on Friday. The stock has a market cap of $4.46 million and a PE ratio of -0.40. Lakewood-Amedex Biotherapeutics has a twelve month low of $1.66 and a twelve month high of $98.20. The firm’s fifty day moving average price is $2.36.

Lakewood-Amedex Biotherapeutics (NASDAQ:LABT) last released its quarterly earnings data on Friday, August 14th. The company reported ($2.75) earnings per share (EPS) for the quarter. On average, analysts predict that Lakewood-Amedex Biotherapeutics will post 4.96 earnings per share for the current fiscal year.

Lakewood-Amedex Biotherapeutics Company Profile

We are a biotechnology company focused on leveraging unique, pioneering science to address unmet needs in the treatment of infectious diseases, improving patient outcomes, and significantly reducing the threat posed by antibiotic-resistant bacterial strains, including methicillin resistant Staphylococcus aureus (MRSA), vancomycin resistant Enterococci species (VRE), and others. Antimicrobial resistance (AMR) represents a growing global health crisis, being directly responsible for 1.27 million deaths annually and contributing to nearly 5 million deaths worldwide.